Alphanate SD/HT

ApprovedBiologic

GGrifols Biologicals, LLC

Alphanate SD/HT is one of 34 biologic programs targeting Severe Hemophilia a. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Hemophilia aActive, not recruiting

Severe Hemophilia aApproved

Active, not recruiting

Competition

Competitive Landscape

59 competitors in Severe Hemophilia a

#DrugCompanyPhaseTrials

Hemlibra

Roche

Phase 3

3 2

Efanesoctocog Alfa

Sanofi

Phase 3

2 3

Rfviiifc

BBioverativ Therapeutics Inc.

Approved

3 4

Advate

Takeda

Phase 3

4 5

Rituxan

Roche

Phase 2

1 6

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

4 7

Bypassing Agents

Roche

Phase 3

1 8

Adynovate

Takeda

Approved

2 9

Recombinant Human Coagulation FVIII

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 10

Recombinant Factor VIII

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Post-ApprovalActive, not recruiting

Efficacy

NCT00555555

Clinical

Trials by Indication[1]

Efficacy1 trial

Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients

Active, not recruiting·GGrifols Biologicals, LLC·Phase 4·NCT00555555·15 enrolled

Severe Hemophilia a1 trial

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Completed·GGrifols Biologicals, LLC·Phase 4·NCT00323856·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Alphanate SD/HT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alphanate SD/HT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alphanate SD/HT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Grifols Biologicals, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: GGrifols Biologicals, LLC

Alphanate SD/HT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Efficacy1 trial

Severe Hemophilia a1 trial

References

Drug Info

Quick Facts

Related News